Next Article in Journal
NKG2A/CD94 Is a New Immune Receptor for HLA-G and Distinguishes Amino Acid Differences in the HLA-G Heavy Chain
Next Article in Special Issue
SARS-CoV-2 Evolutionary Adaptation toward Host Entry and Recognition of Receptor O-Acetyl Sialylation in Virus–Host Interaction
Previous Article in Journal
Characterisation of the Effect of the Spatial Organisation of Hemicellulases on the Hydrolysis of Plant Biomass Polymer
Previous Article in Special Issue
Glycosylation of Zika Virus is Important in Host–Virus Interaction and Pathogenic Potential
Review

Sialic Acid-Siglec Axis as Molecular Checkpoints Targeting of Immune System: Smart Players in Pathology and Conventional Therapy

1
Department of Clinical Pharmacology, Medical University of Bialystok, Waszyngtona 15A, 15-274 Bialystok, Poland
2
Department of Experimental Pharmacology, Medical University of Bialystok, Szpitalna 37, 15-295 Bialystok, Poland
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(12), 4361; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21124361
Received: 29 May 2020 / Revised: 17 June 2020 / Accepted: 17 June 2020 / Published: 19 June 2020
(This article belongs to the Special Issue Cellular Interaction in Immunity)
The sialic acid-based molecular mimicry in pathogens and malignant cells is a regulatory mechanism that leads to cross-reactivity with host antigens resulting in suppression and tolerance in the immune system. The interplay between sialoglycans and immunoregulatory Siglec receptors promotes foreign antigens hiding and immunosurveillance impairment. Therefore, molecular targeting of immune checkpoints, including sialic acid-Siglec axis, is a promising new field of inflammatory disorders and cancer therapy. However, the conventional drugs used in regular management can interfere with glycome machinery and exert a divergent effect on immune controlling systems. Here, we focus on the known effects of standard therapies on the sialoglycan-Siglec checkpoint and their importance in diagnosis, prediction, and clinical outcomes. View Full-Text
Keywords: sialic acid; Siglec; checkpoint axis; immune system; pathology; conventional therapy sialic acid; Siglec; checkpoint axis; immune system; pathology; conventional therapy
Show Figures

Figure 1

MDPI and ACS Style

Wielgat, P.; Rogowski, K.; Niemirowicz-Laskowska, K.; Car, H. Sialic Acid-Siglec Axis as Molecular Checkpoints Targeting of Immune System: Smart Players in Pathology and Conventional Therapy. Int. J. Mol. Sci. 2020, 21, 4361. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21124361

AMA Style

Wielgat P, Rogowski K, Niemirowicz-Laskowska K, Car H. Sialic Acid-Siglec Axis as Molecular Checkpoints Targeting of Immune System: Smart Players in Pathology and Conventional Therapy. International Journal of Molecular Sciences. 2020; 21(12):4361. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21124361

Chicago/Turabian Style

Wielgat, Przemyslaw, Karol Rogowski, Katarzyna Niemirowicz-Laskowska, and Halina Car. 2020. "Sialic Acid-Siglec Axis as Molecular Checkpoints Targeting of Immune System: Smart Players in Pathology and Conventional Therapy" International Journal of Molecular Sciences 21, no. 12: 4361. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21124361

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop